PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 02: Articles 501-1000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
  2. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
  3. A comparison between the vaginal ring and oral contraceptives.
  4. Concerns about contraceptive side effects among young Latinas: a focus-group approach.
  5. Confidential reproductive health services for minors: the potential impact of mandated parental involvement for contraception.
  6. Contraception by Ushercell (cellulose sulfate) in formulation: duration of effect and dose effectiveness.
  7. Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial.
  8. Contraceptive efficacy and safety of DMPA-SC.
  9. Contraceptive efficacy of antimicrobial peptide Nisin: in vitro and in vivo studies.
  10. Contraceptive failure in the United States.
  11. Contraceptive risk and compensatory behaviour in young people in education post-16 years: a cross-sectional study.
  12. Contraceptive use and consistency in U.S. teenagers' most recent sexual relationships.
  13. Contraceptive use and risk of unintended pregnancy in California.
  14. Contraceptive use in HIV-positive women.
  15. The contraceptive vaginal ring (NuvaRing) hemostasis: a comparative study.
  16. The contraceptive vaginal ring, NuvaRing, antimycotic co-medication.
  17. Cost efficiency in maternal and child health and family planning service delivery in Bangladesh: implications for NGOs.
  18. Costs and net health effects of contraceptive methods.
  19. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 micrograms of ethinylestradiol.
  20. Decentralization and integration of health and family planning services in Bangladesh.
  21. The delayed contraceptive revolution in Guatemala. [La postergada revolución anticonceptiva en Guatemala.]
  22. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls.
  23. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception.
  24. Diffusion of Innovations: family planning in developing countries.
  25. Do family-planning workers in China support provision of sexual and reproductive health services to unmarried young people?
  26. Do Mexico City pharmacy workers screen women for health risks when they sell oral contraceptive pills over-the-counter? [¿El personal de farmacia de Ciudad de México realiza detección de riesgos de salud entre las mujeres cuando les venden píldoras anticonceptivas de venta libre?]
  27. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 micrograms or 30 micrograms) and levonorgestrel (100 micrograms or 150 micrograms) on lipoprotein metabolism.
  28. Effect of advanced provision of emergency contraception on women's contraceptive behaviour: a randomized controlled trial.
  29. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
  30. Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function.
  31. Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants.
  32. Effect of four oral contraceptives on hemostatic parameters.
  33. The effect of hormonal contraception on genital tract shedding of HIV-1.
  34. Effect of hormonal emergency contraception on bleeding patterns.
  35. Effectiveness of preabortion counseling on postabortion contraceptive use.
  36. Effects of a community-based sex education and reproductive health service program on contraceptive use of unmarried youths in Shanghai.
  37. Effects of hormonal contraception on bone mineral density after 24 months of use.
  38. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 micrograms drospirenone.
  39. Efficacy of nonhormonal vaginal contraceptives from a hydrogel delivery system.
  40. Efficacy of the new TwoDay Method of family planning.
  41. Emergency contraception and morality: reflections of health care workers and clients.
  42. Emergency contraception use is correlated with increased condom use among adolescents: results from Mexico. [El uso de anticoncepción de emergencia es correlativo a un aumento del uso de condones entre los adolescentes: resultados en México.]
  43. Emergency contraception with levonorgestrel for teenagers -- efficacy, tolerability, and level of information awareness.
  44. Emergency contraception: prescribing practices of general internists compared with other primary care physicians.
  45. Emergency contraception: who are the users?
  46. Emergency contraception: why can't you give it away? Qualitative findings from an evaluation of advance provision of emergency contraception.
  47. Emergency contraceptive pills in Sweden: evaluation of an information campaign.
  48. Emergency contraceptive pills over-the-counter: a population-based survey of young Swedish women.
  49. Enhancing oral contraceptive success: the potential of new formulations.
  50. Ethnic Chinese women's perceptions about condoms, withdrawal and rhythm methods of birth control.
  51. An evaluation of economics and acceptability of screening for Chlamydia trachomatis infection, in women attending antenatal, abortion, colposcopy and family planning clinics in Scotland, UK.
  52. An evaluation of the use of the transdermal contraceptive patch in adolescents.
  53. Ex vivo analysis of HIV-1 co-receptors at the endocervical mucosa of women using oral contraceptives.
  54. Expanded state-funded family planning services: estimating pregnancies averted by the Family PACT Program in California, 1997-1998.
  55. Factors associated with contraceptive use in late- and post-apartheid South Africa.
  56. Failed contraception? [letter]
  57. Failure of family-planning referral and high interest in advanced provision emergency contraception among women contacted for STD partner notification.
  58. Family planning and sexual health organizations: management lessons for health system reform.
  59. Fertility and parental consent for minors to receive contraceptives.
  60. FFPRHC Guidance (January 2004). The copper intrauterine device as long-term contraception.
  61. FFPRHC Guidance (July 2004). Contraceptive choices for breastfeeding women.
  62. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
  63. Follicular growth during contraceptive pill or vaginal ring treatment depends on the day of ovulation in the pretreatment cycle.
  64. Future developments in hormonal contraception.
  65. Gender inequality, family planning, and maternal and child care in a rural Chinese county.
  66. Hormonal contraception and risk of cervical infections among HIV-1-seropositive Kenyan women.
  67. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections.
  68. How family planning ideas are spread within social groups in rural Malawi.
  69. Immediate monthly combination contraception to facilitate initiation of the depot medroxyprogesterone acetate contraceptive injection.
  70. Impact of common contraceptive methods on quality of life and sexual function in Hong Kong Chinese women.
  71. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.
  72. Increased titer of anti-beta 2-glycoprotein I IgG antibody among factor V Leiden carriers during oral contraceptive use.
  73. Interleukin-6 and antiphospholipid antibodies in women with contraceptive-related thromboembolic disease.
  74. Intrauterine contraception: the role of general practitioners in four Dutch general practices.
  75. Intrauterine contraceptive devices and risk of pelvic inflammatory disease: standard of care in high STI prevalence settings.
  76. Is previous use of hormonal contraception associated with a detrimental effect on subsequent fecundity?
  77. Knowledge of emergency contraception among women aged 18 to 44 in California.
  78. Lactational amenorrhea as a method of family planning in Egypt.
  79. Lipid profile in women over 35 years old using triphasic combined oral contraceptives. [Perfil lipídico de las mujeres de más de 35 años que utilizan anticonceptivos orales combinados trifásicos.]
  80. Low-dose mifepristone for contraception: a weekly versus planned postcoital randomized pilot study.
  81. Male hormonal contraception.
  82. Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men.
  83. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression.
  84. Marriage and contraception among the Pare of northern Tanzania.
  85. Measuring family planning sustainability at the outcome and programme levels.
  86. Meeting the contraceptive needs of unmarried young people: attitudes of formal and informal sector providers in Vientiane Municipality, Lao PDR.
  87. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections.
  88. Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception.
  89. Mind the gap: responding to the global funding crisis in family planning.
  90. Minimum effectiveness of the levonorgestrel regimen of emergency contraception.
  91. New delivery systems in contraception: vaginal rings.
  92. The North Carolina DIAL EC project: increasing access to emergency contraceptive pills by telephone.
  93. An open-label randomized comparative study of oral contraceptives between medications containing 3 micrograms drospirenone / 30 micrograms ethinylestradiol and 150 micrograms levonogestrel / 30 ethinylestradiol in Thai women.
  94. Opportunistic screening for genital Chlamydia trachomatis infection and partner follow-up in family planning clinics in three Scottish cities.
  95. Oral contraceptive non-compliance in rural Bangladesh.
  96. Oral contraceptive use and risk of diabetes among Chinese women.
  97. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
  98. Oral contraceptives and cervical cancer: critique of a recent review.
  99. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding.
  100. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use.
  101. Precautionary tales: condom and contraceptive use among young Australian apprentices.
  102. The prevalence rates of domestic abuse in women attending a family planning clinic.
  103. Progestogen-only contraception in women at high risk of venous thromboembolism.
  104. A prospective open-label study to evaluate the effects of the oral contraceptive Harmonet (gestodene 75/EE20) on body fat. [Estudio prospectivo de etiqueta abierta para evaluar los efectos del anticonceptivo oral Harmonet (gestoden 75/EE20) sobre la grasa corporal.]
  105. A prospective study of pregravid oral contraceptive use in relation to fetal growth.
  106. Psychological effect of the oral contraceptive formulation containing 3 micrograms of drospirenone plus 30 micrograms of ethinyl estradiol.
  107. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
  108. A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception.
  109. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception.
  110. Rationale for new oral contraceptive dosing.
  111. Re-audit of referral compliance of chlamydia-positive women from a family planning clinic.
  112. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations.
  113. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment.
  114. Repeat induced abortions and contraceptive practices among unmarried young women seeking an abortion in China.
  115. Reproductive consequences of contraceptive failure in 19 developing countries.
  116. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study.
  117. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study.
  118. The role of emergency contraception.
  119. The role of misconceptions on Latino women's acceptance of emergency contraceptive pills.
  120. Safety concerns and health benefits associated with oral contraception.
  121. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
  122. Sex hormone -- binding globulin -- a surrogate marker for the prothrombotic effects of combined oral contraceptives.
  123. Sexual behavior of women taking low-dose oral contraceptive containing 15 micrograms ethinylestradiol / 60 micrograms gestodene.
  124. Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 micrograms of drospirenone plus 30 micrograms of ethinyl estradiol: observational study in young postadolescent women.
  125. Side effects of the Yuzpe regimen of emergency contraception and two modifications.
  126. Social identity and community effects on contraceptive use and intentions in southern Ethiopia.
  127. Sociocultural and religious influences on the normative contraceptive practices of Latino women in the United States.
  128. State of the art in hormonal contraception: an overview.
  129. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.
  130. What women believe about oral contraceptives and the effect of counseling.
  131. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives.
  132. Women's autonomy, education and employment in Oman and their influence on contraceptive use.
  133. What can a woman do if she misses combined oral contraceptives (COCs)? Family planning. Selected Practice Recommendations update.
  134. Abortion and contraception in Romania: a strategic assessment of policy, programme and research issues. Report.
  135. The effects of contraception on obstetric outcomes. [Efectos de la anticoncepción en resultados obstétricos.]
  136. The Glion Call to Action on Family Planning and HIV / AIDS in Women and Children, 3-5 May 2004.
  137. Donor support for contraceptives and condoms for STI / HIV prevention, 2002.
  138. When will Bangladesh reach replacement-level fertility? The role of education and family planning services.
  139. Uganda family planning programs: lessons from the field. Partnering with communities and district health teams.
  140. In Paraguay, both IUDs and contraceptive pills come with "strings attached". [En Paraguay, la provisión de dispositivos intrauterinos y de píldoras anticonceptivas está sujeta a demasiadas condiciones.]
  141. Choice of contraceptive methods by women attending a public health clinic. [Escolha de métodos contraceptivos entre usuárias de um serviço público de saúde.]
  142. Family planning and female sterilization: analysis of work by a team of health providers. [Planejamento familiar e laqueadura tubária: análise do trabalho de uma equipe de saúde.]
  143. Male views of contraceptive methods in a rural community in Bahia State, Brazil. [A visao masculina sobre métodos contraceptivos em uma comunidade rural da Bahia, Brasil.]
  144. Emergency contraception for conflict-affected settings. A Reproductive Health Response in Conflict Consortium distance learning module.
  145. Effectiveness and acceptability of progestogens in combined oral contraceptives -- a systematic review.
  146. Emergency contraceptive pills should be available over-the-counter.
  147. Emergency contraception: an important and underutilized contraceptive option.
  148. The unfinished agenda: meeting the need for family planning in less developed countries.
  149. Islam and family planning.
  150. Philippine business leaders spearhead drive for family planning.
  151. Governments must invest in international family planning and AIDS prevention.
  152. Biomedical research. Potential long-acting male contraceptive studied. [Investigación Biomédica. Estudio potencial de un anticonceptivo masculino de acción prolongada.]
  153. Family Planning. Door-to-door delivery enhances women's status in Bangladesh.
  154. Review of field experiences: integration of family planning and PMTCT services.
  155. Russia postabortion care. Postabortion family planning counseling and services lead to increased contraceptive use.
  156. Bangladesh access. High quality of care during outreach linked to contraceptive use.
  157. Peru quality of care. Targeted counseling enhances client knowledge and contraceptive use. [Perú: El asesoramiento específico aumenta los conocimientos de los clientes y el uso de anticonceptivos.]
  158. The policy circle: a framework for analyzing the components of family planning, reproductive health, maternal health, and HIV / AIDS policies.
  159. An analysis of family planning content in HIV / AIDS, VCT, and PMTCT policies in 16 countries.
  160. Provision and use of family planning in the context of HIV / AIDS in Zambia: perspectives of providers, family planning and antenatal care clients, and HIV-positive women.
  161. Provision and use of family planning in the context of HIV / AIDS in Kenya: perspectives of providers, family planning and antenatal care clients, and HIV-positive women.
  162. Family planning market segmentation in Jordan: an analysis of the family planning market in Jordan to develop an effective and evidence-based strategic plan for attaining contraceptive security.
  163. Country analysis of family planning and HIV / AIDS: Ethiopia.
  164. Ensuring contraceptive security within new development assistance mechanisms.
  165. Key facts about emergency contraception.
  166. Resources for emergency contraceptive pill programming: a toolkit.
  167. The politics of emergency contraception.
  168. Title X: the nation's cornerstone federal family planning program.
  169. Insurance coverage for contraception improves the health of women and families.
  170. Insurance coverage for contraception: state laws and regulations.
  171. Women -- including young women -- need over-the-counter access to safe, effective emergency contraception.
  172. Government-mandated parental involvement in family planning services threatens young people's health.
  173. Youth and contraception: needs and challenges.
  174. Female sterilization: the most popular method of modern contraception.
  175. Contraception for women on first-line antiretrovirals (ARVs)
  176. Contraceptive security: what you can do.
  177. Emergency contraception in California. Findings from a 2003 Kaiser Family Foundation survey.
  178. A series of national surveys of teens about sex: birth control and prevention. Questionnaire and detailed results.
  179. Birth control and protection. A series of national surveys of teens about sex.
  180. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.
  181. WHO updates medical eligibility criteria for contraceptives.
  182. Analysis of adoption preference of family planning methods through multiple logistic regression.
  183. Assessment of unmet need for contraception in an urban slum of Delhi.
  184. Limiting factors in contraceptive acceptance in urban slum with or without ICDS.
  185. Acceptability of contraceptive methods among urban eligible couples of Imphal, Manipur.
  186. The impact of unmet family planning needs on women's health. Evidence from a research study in Madhya Pradesh, India.
  187. Family planning practices and attitudes in selected municipalities in Lanao del Sur, Autonomous Region of Muslim Mindanao.
  188. Statutory rape reporting and family planning programs: moving beyond conflict.
  189. Contraceptive coverage: a 10-year retrospective.
  190. FDA delays its decision on the sale of emergency contraception.
  191. Doing more for less: study says state Medicaid family planning expansions are cost-effective.
  192. Does discussion of family planning improve knowledge of partner's attitude toward contraceptives?
  193. Provision of family planning services in Lesotho.
  194. Family planning and women's lives in rural China.
  195. Whatever happened to family planning and, for that matter, reproductive health.
  196. Political management in the Indonesian family planning program.
  197. The Glion Call to Action on family planning and HIV / AIDS in women and children.
  198. Integrating family planning and PMTCT services.
  199. Integrating lessons learned from family planning [editorial]
  200. FamPlan. Version 4. A computer program for projecting family planning requirements.
  201. Attitudes of college students toward contraceptives: a consideration of gender differences.
  202. Expanding contraceptive options and access for youth. Education, services, and products can help protect against unintended pregnancy and STIs.
  203. Integrating family planning and voluntary counseling and testing services in Kenya.
  204. Family planning and the prevention of mother-to-child transmission of HIV: a review of the literature.
  205. Contraceptives and HIV.
  206. Averting HIV-infected births. Integrating family planning services can help achieve goal.
  207. Case studies. Uganda: integrating family planning into VCT.
  208. Family planning and HIV service integration. Potential synergies are recognized.
  209. HIV services for family planning clients.
  210. Integrating family planning into VCT services. The feasibility of integration is demonstrated in Africa and the Caribbean.
  211. Preventing HIV / AIDS through family planning. [Prevención del VIH/SIDA a través de la planificación familiar.]
  212. The logistics handbook: a practical guide for supply chain managers in family planning and health programs.
  213. Serbia family planning and reproductive health assessment. Final report.
  214. Regional contraceptive security report: Latin America and the Caribbean. Findings and recommendations. [Informe sobre seguridad anticonceptiva regional: América Latina y el Caribe. Datos y recomendaciones.]
  215. Contraceptive security in Peru: assessing strengths and weaknesses, September 1-12, 2003. [Seguridad anticonceptiva en Perú: evaluación de fortalezas y debilidades, 1º - 12 de septiembre de 2003.]
  216. Contraceptive security in Nicaragua: assessing strengths and weaknesses, February 2-13, 2004. [Seguridad anticonceptiva en Nicaragua: evaluación de fortalezas y debilidades, 2 - 13 de febrero de 2004.]
  217. Contraceptive security in Honduras: assessing strengths and weaknesses, April 26 - May 7, 2004. [Seguridad anticonceptiva en Honduras: evaluación de fortalezas y debilidades, 26 de abril - 7 de mayo de 2004.]
  218. Contraceptive security in Paraguay: assessing strengths and weaknesses, March 8-19, 2004. [Seguridad anticonceptiva en Paraguay: evaluación de fortalezas y debilidades, 8 -19 de febrero de 2004.]
  219. Advocacy training manual for social acceptance of family planning in the Philippines. Draft.
  220. Contraceptive practice and the experience of side effects in Quirino province, Philippines.
  221. A political economy perspective on achieving contraceptive self-reliance in Turkey.
  222. Facilitators module: group counseling for promoting modern family planning.
  223. Project LUCENT: Baseline survey on family planning knowledge, attitude and practices among Filipino men and women.
  224. Training Latin American Ministry of Health service providers on emergency contraception. [Capacitación sobre anticoncepción de emergencia para los prestadores de servicios del Ministerio de Salud de América Latina.]
  225. Contraceptive security: ready lessons. 5. Using data for decision making. [Sécurité contraceptive : leçons. 5. Utilisation de données comme aide à la prise de décisions.]
  226. Contraceptive security: ready lessons. 4. Advocating for sustained commitment. [Seguridad anticonceptiva: lecciones aprendidas. 4. Defensa de un compromiso sostenido.]
  227. Contraceptive security: ready lessons. 3. Taking a whole market approach.
  228. Contraceptive security: ready lessons. 2. Doing a joint assessment.
  229. Contraceptive security: ready lessons. 1. Raising awareness and commitment.
  230. Contraceptive security: ready lessons. Overview.
  231. Strengthening Social Acceptance of Family Planning in the Philippines: a communication and advocacy project. USAID Contract No. 492-C-00-02-00019-00. Annual report (Year 2): October 1, 2003 to September 30, 2004.
  232. Approach to oral contraceptive nuisance side effects.
  233. Oral contraceptive prescribing: should body weight influence choice of pill?
  234. What do young people from Mostar, Bosnia and Herzegovina know about contraception and sexual health?
  235. Assessment of quality of care in family planning services in Jimma zone, southwest Ethiopia.
  236. Screening family planning needs: an operations research project in Guatemala. [Detección de las necesidades de planificación familiar: proyecto de investigación operativa en Guatemala.]
  237. Use of hormonal contraceptives and occurrence of pregnancy-related pelvic pain: a prospective cohort study in Norway.
  238. Hormonal contraception in Chinese men: variations in suppression of spermatogenesis with injectable testosterone undecanoate and levonorgestrel implants.
  239. Periodic well-woman visit: individualized contraceptive care.
  240. Administration of hormonal contraceptive drugs: quick reference guide for clinicians.
  241. Plateaus during the rise of contraceptive prevalence.

     

  242. Repositioning family planning: an Advance Africa strategy.
  243. Using the birth spacing perspective to launch family planning services in IDP sites: Advance Africa's experiences in Democratic Republic of the Congo and Angola. [Recours à la perspective d'espacement des naissances pour le lancement de services de planification familiale dans des sites d'accueil de personnes déplacées : Expériences d'Advance Africa en République Démocratique du Congo et en Angola.]
  244. Menstrual regulation practices in Bangladesh: an unrecognized form of contraception.
  245. Barriers to male participation in family planning in West Timor.
  246. Barriers to family planning service use among the urban poor in Pakistan.
  247. Screening family planning needs: an operations research project in Guatemala. [Detección de las necesidades de planificación familiar: proyecto de investigación de operaciones en Guatemala.]
  248. Premarital sexuality and unmet need of contraception among youth-evidence from two cities of India.
  249. Madhya Pradesh target couple survey, 1996 - fertility, child mortality and family planning.
  250. Out-of-pocket expenditures for oral contraceptives and number of packs per purchase.
  251. FDA rejects over the counter status for emergency contraceptive.
  252. Progesterone emergency contraception.
  253. Oral contraceptive use may reduce risk of cardiovascular events, cancer.
  254. Induced abortion and concurrent adoption of contraception in the rural areas of India (an ICMR Task Force Study)
  255. Microbial and cytopathological study of intrauterine contraceptive device users.
  256. 2004 contraception guidelines [editorial] [Directives cliniques sur la contraception 2004.]
  257. Acceptability of an existing, female-controlled contraceptive method that could potentially protect against HIV: a comparison of diaphragm users and other method users.
  258. Access to contraceptive services among unmarried young people in the north-east of China.
  259. Acoustic measures of vocal stability during different speech tasks in young women using oral contraceptives: a retrospective study.
  260. Adaptation of a political bureaucracy to economic and institutional change under socialism: the Chinese state family planning system.
  261. Advance Africa project proceedings report: Repositioning Family Planning in Africa Working Assembly.
  262. Advance EC pills don't decrease contraceptive use.
  263. Adverse event reports spark discussions on safety of Evra contraceptive patch.
  264. Analysis of the family planning hotline: questions and answers. Strengthening Social Acceptance Of Family Planning in the Philippines: A Communication and Advocacy Project.
  265. Angiogenic factors and the endometrium following long term progestin only contraception.
  266. Answering questions on emergency contraception.
  267. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception.
  268. Antibiotic prophylaxis for intrauterine contraceptive device insertion.
  269. Are oral contraceptive use and pregnancy complications risk factors for atopic disorders among offspring?
  270. Are routine breast and pelvic examinations necessary for women starting combined oral contraception?
  271. Association between birth control pills and voice quality.
  272. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults.
  273. Awareness and practices of contraception among Pakistani women attending a tertiary care hospital.
  274. AWHONN urges approval of OTC emergency contraception. Expert statement provided as FDA advisory panels discuss access.
  275. Barriers to effective contraception and strategies for overcoming them among adolescent mothers.
  276. The benefit of health insurance coverage of contraceptives in a population-based sample.
  277. The best contraception is survival of the infants. [Den beste prevensjon er barns overlevelse.]
  278. Birth control and contraception for teenagers.
  279. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive.
  280. Bone density and contraception in adolescent girls.
  281. Bulletin: Emergency contraception moves closer to over-the-counter.
  282. By the way, doctor. How risky are birth control pills? Do birth control pills increase my risk for getting breast and ovarian cancer? If so, how long can I take the pill and still avoid these risks?
  283. California adolescents' use of family planning services [letter]
  284. Canadian access to hormonal contraceptive drug choices.
  285. A case of hysterotomy for removal of an intrauterine contraceptive device and subsequent pregnancy.
  286. Changing men's involvement in reproductive health and family planning.
  287. Check new advances in natural family planning.
  288. Chlamydia testing in contraceptive clinics: who, where, how and why? [editorial]
  289. Choices of contraception.
  290. Chorea and contraceptives: case report with PET study and review of the literature.
  291. Perceived quality of care and contraceptive use among social marketed and commercial health establishment clientele in urban Pakistan.
  292. Personal narratives of adolescent mothers-to-be: contraception, decision making, and future expectations.
  293. Pill remains powerful force in contraception.
  294. Plan B -- the FDA and emergency contraception [letter]
  295. Polish Gynecological Society's recommendations regarding contraception. [Rekomendacje Polskiego Towarzystwa Ginekologicznego w sprawie antykoncepcji.]
  296. Strengthening provider performance in reproductive health and family planning: innovations, lessons learned, and results achieved. End-of-Project Report for JHPIEGO's Training in Reproductive Health Project.
  297. A study of non acceptance of contraceptives among women in Bihar.
  298. Summary of the practice guideline 'Hormonal contraception' (second revision) from the Dutch College of General Practitioners. [Samenvatting van de standaard 'Hormonale anticonceptie' (tweede herziening) van het Nederlands Huisartsen Genootschap.]
  299. Sustainability of Thailand's Family Planning Program: a system dynamics perspective.
  300. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002.
  301. There must be a better way. Contraceptive options for men.
  302. Third generation oral contraceptive use and cardiovascular risk factors.
  303. Third-generation oral contraceptives -- how big is the risk of venous thrombosis? [Tredjegenerasjons p-piller -- hvor stor er risikoen for venos tromboemboIisme?]
  304. A three-dimensional study of endometrial microvessels in women using the contraceptive subdermal levonorgestrel implant system, norplant.
  305. Title X (Ten) National Family Planning Program. Critical women's health program struggles to meet increasing demand.
  306. Towards consensus on good practice in the prescription of emergency contraception for young people.
  307. Transuterine migration as a complication of intrauterine contraceptive devices: six case reports.
  308. Two displaced intrauterine contraceptive devices (copper-T)
  309. Ukraine contraceptive availability assessment. Prepared for USAID / Ukraine.
  310. UN family planning chief urges Bush resume funding.
  311. Universal insurance coverage for contraceptives: a public health imperative [editorial]
  312. USAID contraceptive procurement guide 2005.
  313. Use of contraception and use of family planning services in the United States: 1982-2002.
  314. Use of emergency contraception could halve induced abortion rate in Shanghai, China.
  315. Clinical profile of contraceptive progestins.
  316. Clinical study of emergency contraception with low-dose mifepristone.
  317. A closer look at traditional contraceptive use in Turkey.
  318. Combination injectable contraceptives for contraception.
  319. Combined estrogen-progestin oral contraceptives [letter]
  320. Combined estrogen-progestin oral contraceptives [letter]
  321. Combined estrogen-progrestin oral contraceptives [letter] [author's reply]
  322. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers.
  323. The combined oral contraceptive pill versus bromocriptine to suppress lactation in puerperium: a randomized double blind study.
  324. Combined oral contraceptive pills for treatment of acne.
  325. Combined oral contraceptives and cervical cancer.
  326. Commentary: Fortifying oral contraceptives with folic acid.
  327. Comparative analytical evaluation of thyroid hormone levels in pregnancy and in women taking oral contraceptives: a study from an iodine deficient area.
  328. A comparative study on the effects of a contraceptive vaginal ring NuvaRing and an oral contraceptive on carbohydrate metabolism and adrenal and thyroid function.
  329. Compliance with contraceptive insurance mandates: licit or illicit cooperation in evil?
  330. The condom in relation to prevention of sexually transmitted infections and as a contraceptive method in Sweden.
  331. Context of care and contraceptive method use.
  332. Contraception -- and insertion of intrauterine devices in particular (editorial) [Kontraception -- og isaer oplaegning af spiral.]
  333. Contraception and breast cancer.
  334. Contraception and cancer.
  335. Contraception choice for HIV positive women.
  336. Contraception for adolescents 2003.
  337. Contraception for adolescents: Part One.
  338. Contraception for the adolescent and young adult with congenital heart disease.
  339. Contraception for women on first-line antiretrovirals (ARVs)
  340. Contraception in Europe: accessibility and availability.
  341. Contraceptive behavior of teenagers requesting abortion.
  342. Contraceptive care by family physicians and general practitioners in Japan: attitudes and practices.
  343. Contraceptive choices that work.
  344. Contraceptive measures and HIV transmission protection among women with HIV / AIDS. [Medidas contraceptivas e de proteçao da transmissao do HIV por mulheres com HIV / Aids.]
  345. Contraceptive methods and induced abortions and their association with the risk of colon cancer in Shanghai, China.
  346. Contraceptive options for women with factor V Leiden [letter] [Opciones de anticoncepción para mujeres con factor V Leiden [carta]]
  347. Contraceptive research pregnant with anticipation.
  348. Contraceptive use among Myanmar immigrant workers in southern Thailand in the early phase of work permit legalization: a baseline survey and the short-term results of special health services.
  349. Contraceptive use and behavior in the 21st century: a comprehensive study across five European countries.
  350. Contraceptive use in teens: a threat to bone health? [editorial]
  351. The Coraliance study: non-compliant behavior. Results after a 6-month follow-up of patients on oral contraceptives.
  352. Correlates for consistency of contraceptive use among sexually active female adolescents.
  353. Counseling about contraception among repeated aborters in Ho Chi Minh City, Vietnam.
  354. Creating conditions for greater private sector participation in FP/RH: benefits for contraceptive security.
  355. Depo-Provera: Does this contraceptive choice support the health and well-being of adolescents and young women?
  356. Determinants of spacing contraceptive use among couples in Mumbai: a male perspective.
  357. Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing.
  358. Discussion points for the contraceptive choices for young people.
  359. Ectoplasmic specialization, a testis-specific cell-cell actin-based adherens junction type: is this a potential target for male contraceptive development?
  360. Effect of low-dose oral contraceptive regulon-Gedeon Richter on some hemostatic variables.
  361. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study.
  362. Effect of prolonged use of injectable hormonal contraceptives on blood pressure and body weight.
  363. The effect of rosuvastatin on oestrogen and progestin pharmacokinetics in healthy women taking an oral contraceptive.
  364. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial.
  365. Effect of the oral contraceptive pill on patients undergoing controlled ovarian hyperstimulation.
  366. The effectiveness and acceptability of oral contraceptives (Logest), containing 20 micrograms ethinylestradiol and 75 micrograms gestodene. [Badanie skutecznosci i akceptacji stosowania pigulek antykoncepcyjnych Logest, zawierajacych 20 g etynyloestradiolu i 75 g gestodenu.]
  367. The effects of advance provision of emergency contraception on adolescent women's sexual and contraceptive behaviors.
  368. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women.
  369. Effects of oral contraceptives on glucoregulatory responses to exercise.
  370. Effects of women's schooling on contraceptive use and fertility in Tanzania.
  371. Efficacy of postcoital contraception [letter]
  372. Emergency birth control. Information from your family doctor.
  373. Emergency contraception could lower abortion rate.
  374. Emergency contraception for adolescents: the time to act is now [editorial]
  375. Emergency contraception is not associated with reduction in contraceptive use or an increase in adverse health outcomes.
  376. Emergency contraception kept as prescription only in USA.
  377. Emergency contraception moves into mainstream.
  378. Emergency contraception OTC.
  379. Emergency contraception.
  380. Emergency contraception.
  381. Emergency contraception. A review of primary care issues.
  382. Emergency contraception. Has over the counter availability reduced attendances at emergency departments?
  383. Emergency contraception: an ongoing debate [editorial]
  384. Emergency contraception: do we have the political will to increase access?
  385. Emergency contraception: knowledge and attitudes of family medicine providers.
  386. Emergency contraception: knowledge and practices of tertiary students in Durban, South Africa.
  387. Emergency contraception: latest changes [editorial]
  388. Emergency contraception: latest changes [letter]
  389. Emergency contraception: politics trumps science at the U.S. Food and Drug Administration.
  390. Emergency contraception: the journey so far [letter]
  391. Emergency contraception: the journey so far [letter]
  392. Emergency contraception: the journey so far [letter]
  393. Emergency contraception: what do our patients know?
  394. Emergency contraceptive access to grow in Canada.
  395. Emergency contraceptive pills over-the-counter: practices and attitudes of pharmacy and nurse-midwife providers.
  396. Emergency contraceptive pills.
  397. Emergency contraceptive pills: a review of the recent literature.

     

  398. Endogenous estradiol metabolism during treatment with oral contraceptives.
  399. Endometrial angiopoietin expression and modulation by thrombin and steroid hormones: a mechanism for abnormal angiogenesis following long-term progestin-only contraception.
  400. Estimating the need for family planning / reproductive health service providers in Malawi.
  401. Ethinyl estradiol/drospirenone (Yasmin): a newer oral contraceptive.
  402. Evidence about extending the duration of oral contraceptive use to suppress menstruation.
  403. Experience with Implanon in a northeast London family planning clinic.
  404. Exploring knowledge and attitudes about emergency contraceptive pills among university students in Jamaica. A qualitative approach.
  405. Fact sheet on "emergency contraception" and treatment of victims of sexual assault.
  406. Factor V Leiden and contraception.
  407. Factors influencing discontinuation of intrauterine contraceptive devices: an assessment in the Indian context.
  408. Family planning and psychosocial support for infertile couples.
  409. Family planning care: more than contraception [editorial]
  410. Family planning field workers in Bangladesh as influence agents: some policy implications.
  411. Family planning in Sweden during 100 years. Abortion and contraceptive agents -- from law-breaking to reproductive right. [Fodelsekontroll i Sverige under 100 Ar. Abort och preventivmedel -- fran lagbrott till reproduktiv rättighet.]
  412. Family planning in the balance.
  413. Family planning in the era of HIV / AIDS.
  414. Family planning in the southeast Anatolian Project Region.
  415. Family planning programs: getting the most for the money. [Programmes de planification familiale : en quête d'un retour d'investissement optimal.]
  416. Family planning providers hold the line in salary and staffing levels in 2004.
  417. Family planning waivers work, research shows.
  418. Fertility and contraception: an analysis with national level data.
  419. Fertility awareness-based methods for contraception. [Métodos anticonceptivos basados en la conciencia de la propia fertilidad.]
  420. FFPRHC Guidance (April 2004): the levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health.
  421. FFPRHC Guidance (October 2004). Contraceptive choices for young people.
  422. Folk herbal medicines used in birth control and sexual diseases by tribals of southern Rajasthan, India.
  423. From birth control to menstrual control: the launch of the extended oral contraceptive, "Seasonale".
  424. The future of professional education in natural family planning.
  425. The Global Gag Rule and contraceptive supplies.
  426. Graduation strategy for USAID assistance to the Indonesia National Family Planning Program.
  427. The grand challenge of birth control [letter]
  428. The healthy talk family planning campaign of Massachusetts: a communication-centered approach.
  429. Hemoptysis in a 38-year-old woman receiving an oral contraceptive.
  430. HIV / AIDS and contraceptive methods.
  431. Hormonal contraception: recent advances and controversies.
  432. Hormonally impregnated intrauterine systems (IUSS) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
  433. How safe and effective are existing family planning methods?
  434. Human synthetic peptide vaccine for contraception targeting sperm.
  435. Impact of a school-based comprehensive program for pregnant teens on their contraceptive use, future contraceptive intention, and desire for more children.
  436. Implications of the growing obesity epidemic on contraception and reproductive health [editorial]
  437. Improving Access and Quality of Clinical Family Planning Services in the Public and Private Sectors in Ghana. End of project report for USAID-funded project implemented by EngenderHealth (October 1994- September 2004)
  438. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.
  439. Increase in sexual activity among young Colombian and Peruvian women exceeds rise in contraceptive use. [El aumento de la actividad sexual entre las mujeres jóvenes colombianas y peruanas supera el incremento en el uso de anticonceptivos.]
  440. Information from your family doctor. Birth control using a diaphragm.
  441. Information sources and level of knowledge of contraception issues among Greek women and men in the reproductive age: a country-wide survey.
  442. Integrating family planning and voluntary counseling and testing services in Ghana: a rapid programmatic assessment.
  443. Interaction and contraception.
  444. Interactions with health workers and contraceptive method selection in rural India.
  445. Interventions for emergency contraception.
  446. Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen.
  447. Introducing and negotiating the use of female condoms in sexual relationships: qualitative interviews with women attending a family planning clinic.
  448. Investigating access to reproductive health services using GIS: proximity to services and the use of modern contraceptives in Malawi.
  449. Is chronic pain a distinct diagnosis in primary care? Evidence arising from the Royal College of General Practitioners' Oral Contraception study.
  450. Is male contraceptive on horizon? Trials under way.
  451. John Rock: pioneer in the development of oral contraceptives.
  452. Knowledge and attitudes towards emergency contraception of healthcare providers in a region with a high birth rate.
  453. Knowledge, attitude and practice of family planning among tribals.
  454. Knowledge, behaviour and attitudes on induced abortion and family planning among Sri Lankan women seeking termination of pregnancy.
  455. The limits of conscientious objection -- may pharmacists refuse to fill prescriptions for emergency contraception?
  456. Linkages of antenatal care, child immunization, and family planning behaviour. An observation from NFHS-II (1998-99), India.
  457. Lower-dose injectable contraceptive moves through research pipeline. Self-administration eyed, may give women new option.
  458. Male contraception -- quo vadis?
  459. Male contraception-a topic with many facets.
  460. Male contraceptives: Research examines options.
  461. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men.
  462. Managing genital infection in community family planning clinics: an alternative approach to holistic sexual health service provision.
  463. Measuring performance during the menstrual cycle: a model using oral contraceptives.
  464. Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception.
  465. Medicaid family planning expansions hit stride.
  466. Medicaid: a critical source of support for family planning in the United States.
  467. Medical eligibility criteria for contraceptive use. 3rd ed.
  468. Midterm assessment of the Social Acceptance Project for Family Planning in the Philippines.
  469. Midterm assessment of the Social Acceptance Project for Family Planning in the Philippines. Executive summary.
  470. Migration of an intrauterine contraceptive device (IUD) into the urinary bladder: report of one case. [Migración intravesical de un dispositivo intrauterino: presentacion de un caso.]
  471. Migration of an intrauterine contraceptive device to the ovary.
  472. Minimizing missed opportunities: an approach to decrease the unmet need for family planning.
  473. Missed opportunities: emergency contraception utilisation by young South African women.
  474. Muslim / non-Muslim differentials in fertility and family planning in India.
  475. A national study examining the effect of making emergency hormonal contraception available without prescription.
  476. The "natural" body, God and contraceptive use in the southeastern United States.
  477. A new bead on birth control.
  478. New contraceptive options.
  479. New contraceptive options: patient adherence and satisfaction [editorial]
  480. New contraceptives widen choices, but the Pill still is a top selection.
  481. New labeling for the pill: will it change how you prescribe oral contraceptives?
  482. New product review (September 2003). Norelgestromin / ethinyl oestradiol transdermal contraceptive system (Evra)
  483. New programs broaden contraceptive access.
  484. Nurse prescribing for contraceptive care and sexual health.
  485. Off-licence prescribing in contraception.
  486. One on one. Hormone therapy and the pill. Now that I know about the negative effects of hormone therapy for women after menopause, do I need to be concerned that I took birth control pills earlier in my life? And do I need to be concerned that my daughter is now taking the pill?
  487. Opportunities and pitfalls in integration of family planning and HIV prevention efforts in developing countries.
  488. Oral contraception does not alter single dose saquinavir pharmacokinetics in women.
  489. Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. [Corea inducida por anticonceptivos orales: otro trastorno asociado a los anticuerpos anti-ganglios basales.]
  490. Oral contraceptive update: new agents and regimens.
  491. Oral contraceptives and liver hemangioma: a case-control study.
  492. Oral contraceptives and stroke risk: the debate continues.
  493. Oral contraceptives can affect the metabolism of other drugs. [P-piller kan pavirke metabolismen av andre legemidler.]
  494. Oral contraceptives, menopause hormone replacement therapy, and risk of stroke.
  495. Ovarian follicular development during the use of oral contraception: a review.
  496. Post-meiotic gene products as targets for male contraception.
  497. Potential factors associated with contraceptive intention among adolescent males in Taiwan.
  498. The practice guideline 'Hormonal contraception' (second revision) from the Dutch College of General Practitioners; a response from the perspective of general practice. [De standaard 'Hormonale anticonceptie' (tweede herziening) van het Nederlands Huisartsen Genootschap; reactie vanuit de huisartsgeneeskunde.]
  499. The practice guideline 'Hormonal contraception' (second revision) from the Dutch College of General Practitioners; a response from the perspective of obstetrics and gynaecology (letter) [De standaard 'Horrnonale anticonceptie' (tweede herziening) van het Nederlands Huisartsen Genootschap; reactie vanuit de verloskunde-gynaecologie.]
  500. The practice guideline 'Hormonal contraception' (second revision) from the Dutch College of General Practitioners; a response from the perspective of obstetrics and gynecology. [De standaard 'Hormonale anticonceptie' (tweede herziening) van het Nederlands Huisartsen Genootschap; reactie vanuit de verloskunde-gynaecologie.]

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.